First Time Loading...

Halozyme Therapeutics Inc
NASDAQ:HALO

Watchlist Manager
Halozyme Therapeutics Inc Logo
Halozyme Therapeutics Inc
NASDAQ:HALO
Watchlist
Price: 40.32 USD 1.26%
Updated: May 3, 2024
Section:
 

Relative Value

The Relative Value of one HALO stock under the Base Case scenario is 63.76 USD. Compared to the current market price of 40.32 USD, Halozyme Therapeutics Inc is Undervalued by 37%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HALO Relative Value
Base Case
63.76 USD
Undervaluation 37%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.2
P/S
P/S
Price to Sales
6.2
vs History
90
vs Industry
61
Median 3Y
10.9
Median 5Y
12.4
Industry
8.1
Forward
5.3
More Details
18.2
P/E
P/E
Price to Earnings
18.2
vs History
46
vs Industry
8
Median 3Y
19.9
Median 5Y
17.4
Industry
26.2
Forward
10.7
More Details
13.2
P/OCF
P/OCF
Price to OCF
13.2
vs History
58
vs Industry
10
Median 3Y
19.1
Median 5Y
15.4
Industry
22.6
More Details
14.6
P/FCFE
P/FCFE
Price to FCFE
14.6
vs History
17
vs Industry
8
Median 3Y
10.4
Median 5Y
10.4
Industry
21.3
More Details
61
P/B
P/B
Price to Book Value
61
vs History
15
vs Industry
0
Median 3Y
41.5
Median 5Y
36.9
Industry
2.5
More Details
7.6
EV/S
EV/S
Enterprise Value to Sales
7.6
vs History
92
vs Industry
44
Median 3Y
11.5
Median 5Y
12.4
Industry
7.3
Forward
6.4
More Details
9.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
9.9
vs History
92
vs Industry
41
Median 3Y
14.2
Median 5Y
15.2
Industry
9.1
More Details
14.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
14.8
vs History
63
vs Industry
8
Median 3Y
19.6
Median 5Y
17.7
Industry
4.4
Forward
11.1
More Details
18.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
18.5
vs History
57
vs Industry
7
Median 3Y
22.2
Median 5Y
19.5
Industry
4.3
Forward
13.2
More Details
16.1
EV/OCF
EV/OCF
Enterprise Value to OCF
16.1
vs History
58
vs Industry
9
Median 3Y
21.3
Median 5Y
16.8
Industry
5.4
More Details
16.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
16.8
vs History
55
vs Industry
8
Median 3Y
21.6
Median 5Y
17.2
Industry
3.2
More Details
4.5
EV/IC
EV/IC
Enterprise Value to IC
4.5
vs History
80
vs Industry
35
Median 3Y
4.9
Median 5Y
15.6
Industry
5
More Details

Multiples Across Competitors

HALO Competitors Multiples
Halozyme Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Halozyme Therapeutics Inc
NASDAQ:HALO
5.1B USD 6.2 18.2 14.8 18.5
US
Abbvie Inc
NYSE:ABBV
286B USD 5.3 59.3 12.9 19.7
US
Amgen Inc
NASDAQ:AMGN
167.1B USD 5.9 24.9 17.9 26.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.8B USD 10.4 28.3 22.7 23.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
102.9B USD 7.8 26 17.5 19.2
AU
CSL Ltd
ASX:CSL
133.2B AUD 6.2 35.4 21.5 26.6
US
Gilead Sciences Inc
NASDAQ:GILD
80.4B USD 2.9 165.9 6.7 8.7
US
Moderna Inc
NASDAQ:MRNA
47.3B USD 7 -10.1 -10.9 -9.3
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Biogen Inc
NASDAQ:BIIB
31.2B USD 3.2 26.8 13.7 17.2
KR
Celltrion Inc
KRX:068270
39.2T KRW 18 73.1 44.7 61.6

See Also

Summary
HALO intrinsic value, competitors valuation, and company profile.
DCF Valuation
HALO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
HALO stock valuation using valuation multiples.
Wall Street Estimates
HALO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
HALO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 133,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.